<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7906073</journal-id>
<journal-id journal-id-type="pubmed-jr-id">4424</journal-id>
<journal-id journal-id-type="nlm-ta">J Affect Disord</journal-id>
<journal-id journal-id-type="iso-abbrev">J Affect Disord</journal-id>
<journal-title-group>
<journal-title>Journal of affective disorders</journal-title>
</journal-title-group>
<issn pub-type="ppub">0165-0327</issn>
<issn pub-type="epub">1573-2517</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30029151</article-id>
<article-id pub-id-type="pmc">6273479</article-id>
<article-id pub-id-type="doi">10.1016/j.jad.2018.07.017</article-id>
<article-id pub-id-type="manuscript">NIHMS994319</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>CHRNA7</italic> Deletions are Enriched in Risperidone-Treated Children and Adolescents</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gillentine</surname>
<given-names>Madelyn A.</given-names>
</name>
<degrees>BA</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>White</surname>
<given-names>Janson J.</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grochowski</surname>
<given-names>Christopher M.</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lupski</surname>
<given-names>James R.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schaaf</surname>
<given-names>Christian P.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Calarge</surname>
<given-names>Chadi A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.</aff>
<aff id="A2"><label>2</label>Jan and Dan Neurological Research Institute, Texas Children’s Hospital, Houston, Texas.</aff>
<aff id="A3"><label>3</label>Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas.</aff>
<aff id="A4"><label>4</label>Texas Children’s Hospital, Houston, Texas.</aff>
<aff id="A5"><label>5</label>Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas.</aff>
<author-notes>
<corresp id="CR1">Address correspondence to: Chadi A. Calarge, MD, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, 1102 Bates Avenue, Suite 790, Houston, TX 77030, <email>chadi.calarge@bcm.edu</email>, Christian P. Schaaf, MD, PhD, Department of Molecular and Human Genetics, Baylor College of Medicine, 1250 Moursund Street, Suite 1325, Houston, TX 77030, <email>schaaf@bcm.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>27</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<day>15</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>15</day>
<month>4</month>
<year>2019</year>
</pub-date>
<volume>239</volume>
<fpage>247</fpage>
<lpage>252</lpage>
<!--elocation-id from pubmed: 10.1016/j.jad.2018.07.017-->
<abstract id="ABS1">
<sec id="S1">
<title>Objective:</title>
<p id="P1">Aggression is among the most common indications for referral to child and adolescent mental health services and is often challenging to treat. Understanding the biological underpinnings of aggression could help optimize treatment efficacy. Neuronal nicotinic acetylcholine receptors (nAChRs), specifically the <italic>α</italic>7 nAChR, encoded by the gene <italic>CHRNA7</italic>, have been implicated in aggressive behaviors in animal models as well as humans. Copy number variants (CNVs) of <italic>CHRNA7</italic> are found in individuals with neuropsychiatric disorders, often with comorbid aggression. In this study, we aimed to determine the prevalence of <italic>CHRNA7</italic> CNVs among individuals treated with risperidone, predominantly for irritability and aggression.</p>
</sec>
<sec id="S2">
<title>Methods:</title>
<p id="P2">Risperidone-treated children and adolescents were assessed for <italic>CHRNA7</italic> copy number state using droplet digital PCR and genomic quantitative PCR. Demographic, anthropometric, and clinical data, including the <italic>Child Behavior Checklist</italic> (CBCL), were collected and compared across individuals with and without the <italic>CHRNA7</italic> deletion.</p>
</sec>
<sec id="S3">
<title>Results:</title>
<p id="P3">Of 218 individuals (90% males, mean age: 12.3 ± 2.3 years), 7 (3.2%) were found to carry a <italic>CHRNA7</italic> deletion and one proband carried a <italic>CHRNA7</italic> duplication (0.46%). T-scores for rule breaking, aggression, and externalizing behavior factors of the CBCL were higher in the deletion group, despite taking 58% higher dose of risperidone.</p>
</sec>
<sec id="S4">
<title>Conclusions:</title>
<p id="P4"><italic>CHRNA7</italic> loss may contribute to a phenotype of severe aggression. Given the high prevalence of the deletion among risperidone-treated youth, future studies should examine the therapeutic potential of <italic>α</italic>7 nAChR-targeting drugs to target aggression associated with <italic>CHRNA7</italic> deletions.</p>
</sec>
</abstract>
<kwd-group>
<kwd>
<italic>CHRNA7</italic>
</kwd>
<kwd>15q13.3 microdeletion</kwd>
<kwd>aggression</kwd>
<kwd>disruptive behaviors</kwd>
<kwd>risperidone</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>